BioMed Research International

BioMed Research International / 2018 / Article

Review Article | Open Access

Volume 2018 |Article ID 9156478 | 11 pages | https://doi.org/10.1155/2018/9156478

Insights into the Role of Circadian Rhythms in Bone Metabolism: A Promising Intervention Target?

Academic Editor: Giuseppe Piccione
Received28 Jun 2018
Accepted09 Sep 2018
Published27 Sep 2018

Abstract

Numerous physiological processes of mammals, including bone metabolism, are regulated by the circadian clock system, which consists of a central regulator, the suprachiasmatic nucleus (SCN), and the peripheral oscillators of the BMAL1/CLOCK-PERs/CRYs system. Various bone turnover markers and bone metabolism-regulating hormones such as melatonin and parathyroid hormone (PTH) display diurnal rhythmicity. According to previous research, disruption of the circadian clock due to shift work, sleep restriction, or clock gene knockout is associated with osteoporosis or other abnormal bone metabolism, showing the importance of the circadian clock system for maintaining homeostasis of bone metabolism. Moreover, common causes of osteoporosis, including postmenopausal status and aging, are associated with changes in the circadian clock. In our previous research, we found that agonism of the circadian regulators REV-ERBs inhibits osteoclast differentiation and ameliorates ovariectomy-induced bone loss in mice, suggesting that clock genes may be promising intervention targets for abnormal bone metabolism. Moreover, osteoporosis interventions at different time points can provide varying degrees of bone protection, showing the importance of accounting for circadian rhythms for optimal curative effects in clinical treatment of osteoporosis. In this review, we summarize current knowledge about circadian rhythms and bone metabolism.

1. Introduction

Mammals have developed endogenous circadian clocks in response to Earth’s rotation, characterized by approximately 24-hour cycles. Circadian clocks are maintained by a central regulator, the suprachiasmatic nucleus (SCN), located in the hypothalamus, as well as a peripheral circadian clock system consisting of BMAL1/CLOCK, PERs/CRYs, REV-ERBs/RORs, DECs, and DBP (molecular oscillators). Lesions on the SCN led to disrupted circadian rhythms in terms of temperature, sleep, and locomotor activity, and SCN transplantation restored circadian rhythms in SCN-ablated animals [1, 2]. Similar abnormal circadian rhythms were also observed in clock gene knockout mice [3].

As the master oscillator, SCN organizes the clocks in peripheral tissues through sympathetic pathways and release of glucocorticoids. Heart rate and plasma glucose content are regulated by SCN via the sympathetic nervous system [4, 5]. Moreover, glucocorticoids modulated by the master pacemaker synchronize peripheral circadian rhythms, acting as signals [6, 7]. Entrainment factors such as light and food synchronize the master circadian clock in the SCN. Light information reaches the SCN via the retina and the retinal-hypothalamic tract and serves as the most potent synchronizer. In contrast, food has a much less synchronizing influence on the SCN, with the exception of foods with high palatability [8, 9].

In peripheral tissues, cellular circadian rhythms are maintained by molecular oscillators including BMAL1/CLOCK, PERs/CRYs, REV-ERBs/RORs, DECs and DBP. A complex including “circadian locomotor output cycles kaput” (CLOCK) and “brain and muscle ARNT-like 1” (BMAL1) drives transcription of target genes by binding to E-box elements in promoters, including those of periods (PER1, PER2, and PER3), cryptochromes (CRY1 and CRY2), reverse orientation c-erb α (REV-ERBα) and RAR-related orphan receptor α (RORα). Heterodimers of PERs and CRYs, in turn, repress the transcriptional activities of BMAL1 and CLOCK [10]. Moreover, REV-ERBα suppresses transcription of BMAL1, whereas RORα enhances it [11]. DEC1 and DEC2 repressed CLOCK/BMAL1-induced transactivation of the PER1 promoter by interacting with BMAL1 and competing for E-box elements [12]. BMAL1/CLOCK drives circadian transcription of DBP, which activates transcription of PER1 in conjunction with BMAL1/CLOCK [13, 14] (Figure 1).

Aging and postmenopausal status are the most common causes of primary osteoporosis. Ovariectomy attenuates oscillation of circadian clock genes in murine bones, including CLOCK, BMAL1, CRY2 and REV-ERBα [15]. Although aged mice exhibit normal oscillation amplitudes, peripheral clock responses to exercise and stress stimuli were impaired [16].

Our previous research found that REV-ERBs agonism suppressed RANKL-induced (receptor activator of nuclear factor kappa-Β ligand) osteoclast differentiation and ameliorated ovariectomy-induced bone loss [17]. In this review, we give an overview of correlations between bone metabolism and circadian rhythms in 6 parts: (1) circadian rhythms of bone metabolism; (2) impacts of circadian disruption on bone metabolism; (3) output signals of SCN regulate bone metabolism: sympathetic nervous signals and glucocorticoids; (4) hormones link circadian rhythms with bone metabolism; (5) Peripheral oscillators in bone; (6) implications of circadian rhythms in interventions for bone metabolism disorders.

2. Circadian Rhythm of Bone Metabolism

Bone metabolism exhibits daily patterns, represented by circadian rhythmicity, of bone turnover markers. In a study including 10 healthy men, the bone resorption marker C-terminal cross-linked telopeptide of type I collagen (CTX) displayed a diurnal rhythm, peaking at 05:30 (range 01:30 – 07:30) [18], which was consistent with previous studies [19, 20]. FGF23, a component of osteocyte function, also showed rhythmicity [21]. Similar rhythmicity was not found in sclerostin. Further, no rhythmic variations were observed in osteoprotegerin (OPG) or soluble RANKL (sRANKL) serum levels with a diurnal cycle [22, 23]. Paradoxically, another study showed that OPG displayed a circadian rhythm of a daytime increase and nocturnal decrease [24].

In dromedary camels, osteocalcin reaches its minimum and maximum concentrations of the 24-h period at 1300 h and at 1800 h, respectively [25]. In Gambian, Chinese, and white British adults, levels of plasma CTX, procollagen type 1 N-propeptide (P1NP), N-mid osteocalcin and bone alkaline phosphatase all show rhythmic patterns [26]. Intriguingly, the circadian rhythm of the CTX level can be broken by fasting but not by nasal administration of salmon calcitonin [19].

Using noninvasive Raman microscopy, McElderry et al. found that mineral deposition in calvarial tissue exhibits rhythmicity with a periodicity of 26.8±9.6 hours, with the earliest mineralization events occurring 6 hours after PER1 expression [27]. Similarly, the concentrations of calcium and inorganic phosphorus in rat metaphyseal bones displayed apparent circadian rhythms with peaks during dark periods [28].

In transgenic mice harboring the human osteocalcin promoter linked to a luciferase reporter gene, the maxillomandibular complex, calvaria, tail, carpals, and tarsals all displayed oscillatory patterns of osteogenic activity [29]. Moreover, Zvonic et al. showed that both elements of the circadian transcriptional apparatus (BMAL1/CLOCK/CRYs/PERs) and their mediators (DBP and REV-ERBs) exhibited oscillatory expression profiles in murine calvarial bones [30]. Russell et al. found that bone collagen formation also showed circadian fluctuations. Specifically, during assembly in dark periods, secretion of bone collagenous protein was decreased, as compared to light periods [31].

3. Impact of Circadian Disruption on Bone Metabolism

Sleep and eating are regulated by the circadian clock and can entrain circadian rhythms [32, 33]. Shift work, sleep restriction and fasting are common situations that may lead to circadian misalignments.

Shift workers are reported to have lower bone mineral density (BMD) and increased fracture risk compared to daytime workers [34, 35]. Deficit of 25-OH vitamin D3 caused by decreased open-air exposure may be responsible for this phenomenon [36]. In postmenopausal women, inadequate nocturnal sleep was associated with greater risk of bone loss [37]. Moreover, Swanson et al. reported that 3 weeks of circadian disruption with concurrent sleep restriction led to decreased P1NP and unchanged CTX [38]. A prospective cohort study demonstrated that the overall circadian rhythmicity of rest and activity (pseudo F-statistic) and daytime to nighttime activity ratio (alpha statistic) are associated with areal BMD (aBMD) of the total hip and femoral neck in older men [39]. Intriguingly, exposure to continuous light for 24 weeks is associated with 70% less rhythmicity of the SCN and with early osteoporosis in mice [40].

Eating times can alter the circadian rhythms of DNA synthesis and collagen synthesis in rat tibia [41]. Moreover, food administration leads to a peak of bone resorption. Dividing food into smaller portions blunted this effect and decreased bone resorption in thyroparathyroidectomized animals [42]. Urinary CrossLaps corrected with creatinine (U-CL/Cr), a bone resorption marker, exhibited a significant circadian rhythm, and its fluctuation was dampened by fasting [43].

4. Output Signals of SCN Regulate Bone Metabolism

Circadian signals are transmitted from the central pacemaker SCN to peripheral tissues through the sympathetic nervous system and glucocorticoids [7, 44, 45] (Figure 2). In vivo administration of adrenaline or noradrenaline increased expression of PER1 in the murine liver. Daily injection of adrenaline recovered oscillation of PER1 and PER2 expression in the livers of mice with disrupted SCNs [46]. Glucocorticoids (cortisol in primates and corticosterone in rodents) secreted by adrenocortical steroidogenic cells exhibit circadian rhythms and are involved in regulation of lipid metabolism, glucose homeostasis and cardiovascular tone [47]. SCN lesions in rats altered synchronization of the adrenal corticosterone rhythm [48]. After glucocorticoids bind to glucocorticoid receptors (GRs), these GRs regulate PER1 directly, rather than through PER2 expression, by binding to a glucocorticoid-responsive element [49].

4.1. Sympathetic Nervous Functions

Treatment with β-adrenergic receptor agonist (isoprenaline, Iso) or a synthetic glucocorticoid (dexamethasone) immediately induces human osteoblast SaM-1 cells to express hPER1 and hPER2 and causes circadian oscillation of these two genes, with three peaks observed within 48 h [50]. Moreover, Iso induces rhythmic expression of the osteoblast-related gene Col1a1. In MC3T3-E1 osteoblastic cells, Iso caused oscillations of PER2 expression [51]. Exposure to phenylephrine (PHE), a nonspecific α1-adrenoreceptor (AR) agonist, induced rhythmic expression of bone morphogenetic protein 4 (BMP4) in MC3T3-E1 cells [52], which promotes osteoblast differentiation [53]. Systemic administration of prazosin, a nonspecific α1-AR antagonist, led to decreased bone formation [54]. In addition, α1 β-AR-deficient mice exhibited a lower bone mass compared with wild-type mice [54].

FGF23 is an important cytokine that regulates phosphate and vitamin D metabolism. Iso induced FGF23 expression in the femur, but this was not observed in BMAL1 knockout mice [21].

4.2. Glucocorticoids

SCN orchestrates the daily rhythms of circulating glucocorticoids in 2 ways: (1) regulating the hypothalamic-pituitary-adrenal (HPA) axis through efferent projection to paraventricular nucleus (PVN) [55]; (2) inducing gene expression in the adrenal gland via the sympathetic nervous system [45]. Both PER1 deficient mice and PER2-/- mice exhibit impaired circadian rhythmicity of circulating glucocorticoids [56, 57]. Glucocorticoids further regulate expression of molecular oscillators through binding to glucocorticoid receptor (GR) in peripheral organs, including heart, liver and kidney [7]. Moreover, Wu X et al. revealed that treatment of murine and human bone marrow mesenchymal stem cells (MSC) with dexamethasone (a synthetic glucocorticoid) synchronizes rhythmic expression of BMAL1, PER3, REV-ERBα and REV-ERBβ [58]. CLOCK/BMAL1 in turn interact with GR and suppress GR-induced transcriptional activity [59].

The impact of glucocorticoids on bone metabolism has been comprehensively investigated in the past decades. Physiological glucocorticoids signaling in osteoblast progenitors is essential for maintaining the normal bone density, whereas endogenous glucocorticoid excess and high dose therapeutic glucocorticoids result in osteoporosis by suppressing osteoblast activity and bone formation [55, 60]. In vitro study demonstrated that a glucocorticoid rather than a β-agonist synchronized circadian expression of clock and osteoclast-related genes in osteoclasts [61]. Moreover, dexamethasone injection recovered circadian expression of cathepsin K (CTSK) and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), in adrenalectomized mice [61].

Aside from sympathetic and glucocorticoid signaling, hormones such as melatonin, ghrelin and parathyroid hormone (PTH) can also coordinate circadian rhythms in bone tissue.

5.1. Melatonin

Melatonin is a hormone that regulates sleep and other circadian activities [62]. The SCN regulates melatonin secretion through an inhibitory projection to the paraventricular nucleus, which controls sympathetic output to the pineal gland [63]. Several animal studies have demonstrated that melatonin has beneficial effects on bone metabolism, promoting osteoblast differentiation and suppressing osteoclast formation through oxidative stress reduction and PPARγ suppression [6466]. On the other hand, nocturnal melatonin administration did not improve bone parameters in a blind model using MMTV-Neu transgenic mice [67]. Moreover, a double-blind clinical study demonstrated that there was no difference in bone density, osteocalcin, or NTX between nightly melatonin supplementation and placebo groups [68].

5.2. Ghrelin

Levels of the orexigenic peptide ghrelin exhibit circadian rhythms, and this hormone has been found to induce a phase advance of circadian time in the SCN of about 3 h in vitro [69], causing expression of ghrelin receptor (GHSR). GHSR knockout mice displayed lengthening of their circadian period and greater activity in anticipation of a scheduled meal under constant lighting conditions [70]. In terms of bone metabolism, ghrelin has been shown to promote proliferation and prevent apoptosis of osteoblasts. However, clinical studies of serum ghrelin and BMD demonstrated no correlation between them [71, 72].

5.3. PTH

PTH exhibits a moderate increase between 16:00 and 19:00 and a broader, longer-lasting increase from late evening to early morning, reaching its peak between 02:00 and 06:00 [26, 73]. The direct connection between SCN and PTH secretion remains uncharacterized.

Constitutively active PTH receptors expressed in osteoblasts promote PER1 expression [74]. In organ-cultured murine femur, Okubo et al. revealed that PTH reset the circadian oscillation of PER2::luciferase activity in a time- and dose-dependent manner [75]. Moreover, PTH administration shifts the peak time of PER2::luciferase activity in fracture sites and growth plates [76]

6. Peripheral Oscillators in Bone

Circadian rhythms in peripheral tissues are governed by an autoregulatory transcriptional and translational feedback loop with two branches: the positive transcriptional branch comprised of CLOCK and BMAL1 and the negative branch formed by PERs and CRYs. Circadian regulation genes including REV-ERBs, RORs, DECs and DBP play vital roles in the circadian system. Among these genes, BMAL1 (ARNTL), DBP, NR1D1 (REV-ERBα), NR1D2 (REV-ERBβ), PER1, PER2, and PER3 have been observed to oscillate in all mammalian organs, including the SCN [77, 78]. In human mesenchymal stem cells, expression of the circadian genes CLOCK, BMAL1, PER1, and PER2 displayed rhythmicity [79]. These clock genes play complex roles in bone metabolism (Table 1).


GeneCircadian phenotypeBone phenotype

CLOCKCLOCK mutant mice (): long circadian period (26-28h) [80]
CLOCK knockout mice: robust circadian rhythm in locomotor activity [81]
Clock mutant mice: low bone mass [83]

BMAL1BMAL1-/- mice: impaired locomotor activity [87]BMAL1 knockout mice: low bone mass [87]

PERsPER1-deficient mice: disrupted circadian behavioral rhythms [89]
PER2-deficient mice: disrupted circadian behavioral rhythms [89]
PER1-deficient mice: normal bone volume [91]
PER2-deficient mice: normal bone volume [91]
PER2 PAS domain (): normal bone volume [91]
PER1−/−;: significantly increased bone mass [91]
PER1-/-; PER2-/-: increased bone mass [91]
mice: increased bone volume at 3, 12 and 48 weeks [92]

CRYsCRY1-deficient mice: circadian period 1 hour shorter than wild type [93, 94]
CRY2-deficient mice: circadian period 1 hour longer than wild type [95]
CRY1/2 double knockout mice: arrhythmic in constant darkness [121]
CRY1-deficient mice: not reported
CRY2-deficient mice: increased bone volume [94]
CRY1/2 double knockout mice: high bone volume [91]

REV-ERBsREV-ERBα knockout: average period length significantly shorter [122]
REV-ERBβ knockout: no changes in circadian activity rhythms [123]
REV-ERBα/β double knockout: the free running period length in constant darkness was 2.5 hours shorter [123]
REV-ERBα knockout: not reported
REV-ERBβ knockout: not reported
REV-ERBα/β agonist SR9009: suppressed osteoclast formation and ameliorated OVX-induced bone loss [17]

RORsRORα (sg/sg): shortened period length of the locomotor activity rhythm [102]
RORβ knockout: significant increase in circadian period in constant dark [103]
RORα (sg/sg): osteopenic [104]
RORβ knockout: increase bone mass [108]

DECsDEC1 knockout: longer circadian period under conditions of constant darkness [109]
DEC2 knockout: no changes in circadian activity rhythms [110]
DEC1 or DEC2 knockout: not reported

DBPDBP knockout: shorter period [124]DBP knockout: normal bone volume [120]

6.1. CLOCK

Homozygous CLOCK mutant mice () were reported to display lengthened circadian periods (26-28h in length) [80]. On the other hand, Debruyne et al. reported that CLOCK knockout mice showed robust circadian rhythms in locomotor activity [81]. Subsequent research from the same group demonstrated that NPAS2 functionally substitutes for CLOCK in SCN [82]. In terms of bone metabolism, CLOCK mutant mice exhibit decreased bone density due to reduced expression of Pdia3, a 1, 25-dihydroxy-vitamin D3 receptor [83]. Pdia3 deficiency resulted in reduced relative bone volume (BV/TV) and trabecular number [84].

6.2. BMAL1

Mice deficient in BMAL1 displayed impaired locomotor activity during light-dark (LD) cycles as well as various symptoms of premature aging, including sarcopenia, cataracts, reduced subcutaneous fat and organ shrinkage [85, 86]. Deletion of Bmal1 results in low bone mass [87]. Conditional deletion of Bmal1 in osteoblasts led to reduced bone loss and increased bone resorption. Subsequent coculturing revealed that Bmal1-deficient osteoblasts promote osteoclastogenesis [88].

6.3. PERs

Both PER1- and PER2-deficient mice showed severely disrupted locomotor activity rhythms [89]. Light-induced expression of PER1 and PER2 proteins in the SCN is essential for entrainment [90].

According to Fu et al., mice lacking PER1, PER2 or the PER2 PAS domain () exhibit normal bone volume, whereas PER1−/−; PER2−/− and PER1−/−; mice display increased bone mass. Leptin intracerebroventricular infusion further increases bone mass of PER1−/−; mice [91].

In contrast, Maronde et al. reported that PER2-mutant mice displayed greater bone volumes compared with wild-type mice [92].

6.4. CRYs

The circadian period is 1 hour shorter in CRY1 knockout mice, whereas it is 1 hour longer in CRY2 knockout mice [9395]. CRY2-deficient mice display increased bone volume with low osteoclast activity [94]. Moreover, mice lacking CRY1 and CRY2 exhibit increased bone volume [91]. In a Chinese pediatric cohort, Cry2 rs2292910 was associated with osteoporosis (r = -0.082, p = 0.045) [96].

6.5. REV-ERBs

REV-ERBα and REV-ERBβ were found to regulate hepatic lipid metabolism and skeletal muscle activity in addition to their roles in the cell autonomous clock [97, 98].

Our previous work demonstrated that REV-ERB agonism of SR9009 suppresses osteoclast formation and ameliorates ovariectomy-induced bone loss [17]. REV-ERBα was significantly increased in bone mesenchymal stem cells of old rhesus monkeys, which were characterized by decreased osteogenetic capacity and significantly increased REV-ERBα expression [99]. Furthermore, overexpression of REV-ERBα in bone mesenchymal stem cells inhibited osteogenesis [100].

6.6. RORs

RORs regulate target gene expression by binding to ROR response elements (RORE) containing the RGGTCA consensus motif [101]. RORα (sg/sg) mice displayed a shortened period of the locomotor activity rhythm, while RORβ knockout mice showed a lengthened circadian period in constant dark [102, 103].

RORα (sg/sg) mice with a deletion within the RORα gene are osteopenic compared with wild-type and heterozygote littermates [104], indicating the essential role of RORα in regulation of normal bone metabolism. Further investigation demonstrates that RORα directly activates bone sialoprotein expression, which promotes osteoblast differentiation and matrix mineralization [105].

Expression of RORβ is increased in bone marrow precursor cells of aged mice and bone biopsies from postmenopausal women [106]. Overexpression of RORβ in MC3T3-E1 cells results in decreased bone nodule formation [107]. Knockout of the RORβ gene in osteoblasts promotes expression of osteogenic genes and osteoprotegerin (OPG). Consistent with in vitro results, RORβ-/- mice exhibited increased bone volume [108].

6.7. DECs

DEC1 overexpression extended the periods of clock genes such as DEC1, DEC2 and PER1 [109]. Longer circadian periods under conditions of constant darkness were observed in DEC1 knockout mice [109]. However, DEC2 knockout mice showed no changes in their circadian activity rhythms [110].

After osteogenic induction of MSC in medium containing dexamethasone, beta-glycerophosphate, and ascorbic acid, DEC1 expression gradually increased from day 5 to day 14 [111]. Overexpression of DEC1 in growth plate chondrocytes at the prehypertrophic stage increased mRNA levels of Indian hedgehog, Runx2, and type X collagen, and also promoted alkaline phosphatase activity and mineralization [112].

6.8. DBP

DBP, also known as group-specific component (GC), is a polymorphic protein that binds 85-90% of the total circulating 25-OH vitamin D, which is later transported to the kidneys [113]. In the kidneys, 25-OH vitamin D is converted to the active form of vitamin D, 1,25-dihydroxy-vitamin D (1,25(OH)2D). DBP can also be converted to DBP-macrophage activating factor (DBP-MAF), which directly promotes osteoclast formation [114]. DBP protein and mRNA in the SCN and various peripheral tissues display strong circadian rhythmicity [115]. DBP activates transcription of PER1 in cooperation with CLOCK/BMAL1, which regulate the circadian transcription of DBP through interaction with E boxes [14].

Genotyping based on rs4588 of the GC gene showed that total hip-bone mineral content was associated with GC genotype (p=0.05, ANCOVA) in boys [116]. In women of postmenopausal age, DBP10 (with 10 repeats of TAAA) is associated with lower incidence of bone fracture compared with relevant controls, while DBP11 is related to higher incidence [117]. Another study showed that DBP10 and DBP11 are both associated with lower risks of osteoporosis [118]. A highly suggestive association was found between DBP SNPs (single nucleotide polymorphisms) and spine BMD [119].

Despite associations between DBP genotype and BMD, DBP-deficient mice displayed normal bone volume [120].

7. Implications of Circadian Rhythms in Interventions for Bone Metabolism Disorders

Salmon calcitonin (sCT) is a widely used antiosteoporosis drug. Karsdal et al. assessed CTX-I levels after oral salmon calcitonin intake at three different time points (morning, pre-dinner and evening) in healthy postmenopausal women and found that pre-dinner dosing of oral sCT resulted in optimal efficacy of CTX-I downregulation [125].

PTH is the only FDA approved anabolic drug for osteoporosis. A 12-month clinical investigation demonstrated that morning administration of teriparatide resulted in higher spine BMD compared to evening application [126].

Pulsed electromagnetic fields (PEMF) have been reported as an effective method of preventing osteoporosis, and daytime PEMF application from 9:00 to 15:00 was more effective for prevention of ovariectomy-induced bone loss than nighttime PEMF from 0:00 to 6:00 [127].

Together, these results indicate that circadian rhythms should be considered when treating bone disorders.

8. Conclusions

Bones are organs under dynamic regulation of osteoblasts, osteoclasts, osteocytes, and bone lining cells. Disruption of the balance between these cells leads to diseases such as osteoporosis. The prevalence of osteoporosis and low bone mass is estimated at 10.3% and 43.9% among US adults aged 50 and older, respectively [128]. According to a 2002 national population sample, the annual cost of osteoporosis and fractures in elderly patients in the US was up to $16 billion [129].

Circadian rhythms are regulated by the central oscillator SCN and the peripheral clock system, which contribute to maintaining homeostasis of physiological functions. Circadian arrhythmia is related to disorders such as neurodegenerative diseases [130], metabolic syndrome, cancer [131], and cardiovascular disease [132]. Increasing evidence demonstrates that the circadian clock systems, including the master pacemaker and peripheral circadian machinery, play pivotal roles in maintaining homeostasis of bone metabolism. Circadian disruption due to sleep restriction, shift work, fasting, or knockout of clock genes results in disrupted homeostasis of bone metabolism.

Among the various molecular oscillators, REV-ERBs and RORs are nuclear receptors that can be activated by their natural ligands, heme, and oxygenated sterols, respectively [133]. Various synthetic ligands with high affinities for REV-ERBs and RORs have been developed based on their structures. These ligands display promising therapeutic effects in animal studies, including those on tumors [134], type 1 diabetes [135], atherosclerosis [136], and autism [137]. Combining these studies with our previous findings [17], REV-ERBs and RORs appear to offer promising therapy targets for several disorders, including osteoporosis [138].

In this review, we provide insight into the role of circadian rhythms in bone metabolism, and show evidence that the circadian system may be a promising target of clinical intervention for abnormal bone metabolism.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Chao Song, Feng Li, and Zhong Fang searched literatures, collected data, and prepared the initial manuscript. All coauthors took part in revision of the review.

Acknowledgments

This research was supported by grants from the National Key Research and Development Program of China (no. 2016YFB1101305) and National Nature Science Foundation of China (no. 81472133).

References

  1. C. I. Eastman, R. E. Mistlberger, and A. Rechtschaffen, “Suprachiasmatic nuclei lesions eliminate circadian temperature and sleep rhythms in the rat,” Physiology & Behavior, vol. 32, no. 3, pp. 357–368, 1984. View at: Publisher Site | Google Scholar
  2. W. J. Schwartz and P. Zimmerman, “Lesions of the suprachiasmatic nucleus disrupt circadian locomotor rhythms in the mouse,” Physiology & Behavior, vol. 49, no. 6, pp. 1283–1287, 1991. View at: Publisher Site | Google Scholar
  3. C. H. Ko and J. S. Takahashi, “Molecular components of the mammalian circadian clock,” Human Molecular Genetics, vol. 15, no. 2, pp. R271–R277, 2006. View at: Publisher Site | Google Scholar
  4. W. S. Warren, T. H. Champney, and V. M. Cassone, “The suprachiasmatic nucleus controls the circadian rhythm of heart rate via the sympathetic nervous system,” Physiology & Behavior, vol. 55, no. 6, pp. 1091–1099, 1994. View at: Publisher Site | Google Scholar
  5. A. Kalsbeek, S. La Fleur, C. Van Heijningen, and R. M. Buijs, “Suprachiasmatic GABAergic inputs to the paraventricular nucleus control plasma glucose concentrations in the rat via sympathetic innervation of the liver,” The Journal of Neuroscience, vol. 24, no. 35, pp. 7604–7613, 2004. View at: Publisher Site | Google Scholar
  6. P. Pezük, J. A. Mohawk, L. A. Wang, and M. Menaker, “Glucocorticoids as entraining signals for peripheral circadian oscillators,” Endocrinology, vol. 153, no. 10, pp. 4775–4783, 2012. View at: Publisher Site | Google Scholar
  7. A. Balsalobre, S. A. Brown, L. Marcacci et al., “Resetting of circadian time in peripheral tissues by glucocorticoid signaling,” Science, vol. 289, no. 5488, pp. 2344–2347, 2000. View at: Publisher Site | Google Scholar
  8. J. Mendoza, “Circadian clocks: Setting time by food,” Journal of Neuroendocrinology, vol. 19, no. 2, pp. 127–137, 2007. View at: Publisher Site | Google Scholar
  9. J. Mendoza, M. Angeles-Castellanos, and C. Escobar, “A daily palatable meal without food deprivation entrains the suprachiasmatic nucleus of rats,” European Journal of Neuroscience, vol. 22, no. 11, pp. 2855–2862, 2005. View at: Publisher Site | Google Scholar
  10. H. Dardente and N. Cermakian, “Molecular circadian rhythms in central and peripheral clocks in mammals,” Chronobiology International, vol. 24, no. 2, pp. 195–213, 2007. View at: Publisher Site | Google Scholar
  11. O. B. Sawant, A. M. Horton, O. F. Zucaro et al., “The Circadian Clock Gene Bmal1 Controls Thyroid Hormone-Mediated Spectral Identity and Cone Photoreceptor Function,” Cell Reports, vol. 21, no. 3, pp. 692–706, 2017. View at: Publisher Site | Google Scholar
  12. S. Honma, T. Kawamoto, Y. Takagi et al., “Dec1 and Dec2 are regulators of the mammalian molecular clock,” Nature, vol. 419, no. 6909, pp. 841–844, 2002. View at: Publisher Site | Google Scholar
  13. M. Stratmann, D. M. Suter, N. Molina, F. Naef, and U. Schibler, “Circadian Dbp Transcription Relies on Highly Dynamic BMAL1-CLOCK Interaction with E Boxes and Requires the Proteasome,” Molecular Cell, vol. 48, no. 2, pp. 277–287, 2012. View at: Publisher Site | Google Scholar
  14. S. Yamaguchi, S. Mitsui, L. Yan, K. Yagita, S. Miyake, and H. Okamura, “Role of DBP in the circadian oscillatory mechanism,” Molecular and Cellular Biology, vol. 20, no. 13, pp. 4773–4781, 2000. View at: Publisher Site | Google Scholar
  15. B. J. Smith, G. M. Sutton, X. Wu et al., “Ovariectomy and genes encoding core circadian regulatory proteins in murine bone,” Osteoporosis International, vol. 22, no. 5, pp. 1633–1639, 2011. View at: Publisher Site | Google Scholar
  16. Y. Tahara, Y. Takatsu, T. Shiraishi et al., “Age-related circadian disorganization caused by sympathetic dysfunction in peripheral clock regulation,” npj Aging and Mechanisms of Disease, vol. 3, no. 1, 2017. View at: Publisher Site | Google Scholar
  17. C. Song, P. Tan, Z. Zhang et al., “REV-ERBs agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially,” The FASEB Journal, vol. 32, no. 6, pp. 3215–3228, 2018. View at: Publisher Site | Google Scholar
  18. C. Swanson, S. A. Shea, P. Wolfe et al., “24-hour profile of serum sclerostin and its association with bone biomarkers in men,” Osteoporosis International, vol. 28, no. 11, pp. 3205–3213, 2017. View at: Publisher Site | Google Scholar
  19. P. Qvist, S. Christgau, B. J. Pedersen, A. Schlemmer, and C. Christiansen, “Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting,” Bone, vol. 31, no. 1, pp. 57–61, 2002. View at: Publisher Site | Google Scholar
  20. G. G. Pellegrini, M. M. S. Gonzales Chaves, M. A. Fajardo et al., “Salivary bone turnover markers in healthy pre- and postmenopausal women: Daily and seasonal rhythm,” Clinical Oral Investigations, vol. 16, no. 2, pp. 651–657, 2012. View at: Publisher Site | Google Scholar
  21. M. Kawai, S. Kinoshita, S. Shimba, K. Ozono, and T. Michigami, “Sympathetic activation induces skeletal Fgf23 expression in a circadian rhythm-dependent manner,” The Journal of Biological Chemistry, vol. 289, no. 3, pp. 1457–1466, 2014. View at: Publisher Site | Google Scholar
  22. A. Dovio, D. Generali, M. Tampellini et al., “Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: A rhythmometric analysis,” Osteoporosis International, vol. 19, no. 1, pp. 113–117, 2008. View at: Publisher Site | Google Scholar
  23. M. Shimizu, Y. Onoe, M. Mikumo et al., “Variations in circulating osteoprotegerin and soluble RANKL during diurnal and menstrual cycles in young women,” Hormone Research, vol. 71, no. 5, pp. 285–289, 2009. View at: Publisher Site | Google Scholar
  24. F. Joseph, B. Y. Chan, B. H. Durham et al., “The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 8, pp. 3230–3238, 2007. View at: Publisher Site | Google Scholar
  25. F. A. Al-Sobayil, “Circadian rhythm of bone formation biomarkers in serum of dromedary camels,” Research in Veterinary Science, vol. 89, no. 3, pp. 455–459, 2010. View at: Publisher Site | Google Scholar
  26. J. Redmond, A. J. Fulford, L. Jarjou, B. Zhou, A. Prentice, and I. Schoenmakers, “Diurnal rhythms of bone turnover markers in three ethnic groups,” The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 8, pp. 3222–3230, 2016. View at: Publisher Site | Google Scholar
  27. J.-D. P. McElderry, G. Zhao, A. Khmaladze, C. G. Wilson, R. T. Franceschi, and M. D. Morris, “Tracking circadian rhythms of bone mineral deposition in murine calvarial organ cultures,” Journal of Bone and Mineral Research, vol. 28, no. 8, pp. 1846–1854, 2013. View at: Publisher Site | Google Scholar
  28. J. E. Russell, B. Grazman, and D. J. Simmons, “Mineralization in Rat Metaphyseal Bone Exhibits a Circadian Stage Dependency,” Proceedings of the Society for Experimental Biology and Medicine, vol. 176, no. 4, pp. 342–345, 1984. View at: Publisher Site | Google Scholar
  29. Y. Gafni, A. A. Ptitsyn, Y. Zilberman, G. Pelled, J. M. Gimble, and D. Gazit, “Circadian rhythm of osteocalcin in the maxillomandibular complex,” Journal of Dental Research, vol. 88, no. 1, pp. 45–50, 2009. View at: Publisher Site | Google Scholar
  30. S. Zvonic, A. A. Ptitsyn, G. Kilroy et al., “Circadian oscillation of gene expression in murine calvarial bone,” Journal of Bone and Mineral Research, vol. 22, no. 3, pp. 357–365, 2007. View at: Publisher Site | Google Scholar
  31. J. E. Russell, W. V. Walker, R. J. Fenster, and D. J. Simmons, “In Vitro Evaluation of Circadian Patterns of Bone Collagen Formation,” Proceedings of the Society for Experimental Biology and Medicine, vol. 180, no. 2, pp. 375–381, 1985. View at: Publisher Site | Google Scholar
  32. J. M. Radziuk, “The suprachiasmatic nucleus, circadian clocks, and the liver,” Diabetes, vol. 62, no. 4, pp. 1017–1019, 2013. View at: Publisher Site | Google Scholar
  33. S. M. Abbott, K. J. Reid, and P. C. Zee, “Circadian Rhythm Sleep-Wake Disorders,” Psychiatric Clinics of North America, vol. 38, no. 4, pp. 805–823, 2015. View at: Publisher Site | Google Scholar
  34. I. Quevedo and A. M. Zuniga, “Low bone mineral density in rotating-shift workers,” Journal of Clinical Densitometry, vol. 13, no. 4, pp. 467–469, 2010. View at: Publisher Site | Google Scholar
  35. D. Feskanich, S. E. Hankinson, and E. S. Schernhammer, “Nightshift work and fracture risk: The Nurses' Health Study,” Osteoporosis International, vol. 20, no. 4, pp. 537–542, 2009. View at: Publisher Site | Google Scholar
  36. A. Romano, L. Vigna, V. Belluigi et al., “Shift work and serum 25-OH vitamin D status among factory workers in Northern Italy: Cross-sectional study,” Chronobiology International, vol. 32, no. 6, pp. 842–847, 2015. View at: Publisher Site | Google Scholar
  37. K. Wang, Y. Wu, Y. Yang et al., “The associations of bedtime, nocturnal, and daytime sleep duration with bone mineral density in pre- and post-menopausal women,” Endocrine Journal, vol. 49, no. 2, pp. 538–548, 2015. View at: Publisher Site | Google Scholar
  38. C. M. Swanson, S. A. Shea, P. Wolfe et al., “Bone Turnover Markers After Sleep Restriction and Circadian Disruption: A Mechanism for Sleep-Related Bone Loss in Humans,” The Journal of Clinical Endocrinology & Metabolism, vol. 102, no. 10, pp. 3722–3730, 2017. View at: Publisher Site | Google Scholar
  39. T. S. Rogers, S. Harrison, C. Swanson et al., “Rest-activity circadian rhythms and bone mineral density in elderly men,” Bone Reports, vol. 7, pp. 156–163, 2017. View at: Publisher Site | Google Scholar
  40. E. A. Lucassen, C. P. Coomans, M. van Putten et al., “Environmental 24-hr Cycles Are Essential for Health,” Current Biology, vol. 26, no. 14, pp. 1843–1853, 2016. View at: Publisher Site | Google Scholar
  41. J. E. Russell, D. J. Simmons, B. Huber, and B. A. Roos, “Meal timing as a zeitgeber for skeletal deoxyribonucleic acid and collagen synthesis rhythms,” Endocrinology, vol. 113, no. 6, pp. 2035–2042, 1983. View at: Publisher Site | Google Scholar
  42. R. C. Muhlbauer and H. Fleisch, “The diurnal rhythm of bone resorption in the rat. Effect of feeding habits and pharmacological inhibitors,” The Journal of Clinical Investigation, vol. 95, no. 4, pp. 1933–1940, 1995. View at: Publisher Site | Google Scholar
  43. A. Schlemmer and C. Hassager, “Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption,” European Journal of Endocrinology, vol. 140, no. 4, pp. 332–337, 1999. View at: Publisher Site | Google Scholar
  44. S. Lee, L. A. Donehower, A. J. Herron, D. D. Moore, and L. Fu, “Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice,” PLoS ONE, vol. 5, no. 6, Article ID e10995, 2010. View at: Publisher Site | Google Scholar
  45. A. Ishida, T. Mutoh, T. Ueyama et al., “Light activates the adrenal gland: Timing of gene expression and glucocorticoid release,” Cell Metabolism, vol. 2, no. 5, pp. 297–307, 2005. View at: Publisher Site | Google Scholar
  46. H. Terazono, T. Mutoh, S. Yamaguchi et al., “Adrenergic regulation of clock gene expression in mouse liver,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 100, no. 11, pp. 6795–6800, 2003. View at: Publisher Site | Google Scholar
  47. S. Chung, E. J. Lee, H. K. Cha et al., “Cooperative roles of the suprachiasmatic nucleus central clock and the adrenal clock in controlling circadian glucocorticoid rhythm,” Scientific Reports, vol. 7, 2017. View at: Google Scholar
  48. R. Y. Moore and V. B. Eichler, “Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat,” Brain Research, vol. 42, no. 1, pp. 201–206, 1972. View at: Publisher Site | Google Scholar
  49. T. Yamamoto, Y. Nakahata, M. Tanaka et al., “Acute physical stress elevates mouse Period1 mRNA expression in mouse peripheral tissues via a glucocorticoid-responsive element,” The Journal of Biological Chemistry, vol. 280, no. 51, pp. 42036–42043, 2005. View at: Publisher Site | Google Scholar
  50. S. Komoto, H. Kondo, O. Fukuta, and A. Togari, “Comparison of β-adrenergic and glucocorticoid signaling on clock gene and osteoblast-related gene expressions in human osteoblast,” Chronobiology International, vol. 29, no. 1, pp. 66–74, 2012. View at: Publisher Site | Google Scholar
  51. T. Hirai, K. Tanaka, and A. Togari, “β-adrenergic receptor signaling regulates Ptgs2 by driving circadian gene expression in osteoblasts,” Journal of Cell Science, vol. 127, no. 17, pp. 3711–3719, 2014. View at: Publisher Site | Google Scholar
  52. T. Hirai, K. Tanaka, and A. Togari, “α1-Adrenergic receptor signaling in osteoblasts regulates clock genes and bone morphogenetic protein 4 expression through up-regulation of the transcriptional factor nuclear factor IL-3 (Nfil3)/E4 promoter-binding protein 4 (E4BP4),” The Journal of Biological Chemistry, vol. 289, no. 24, pp. 17174–17183, 2014. View at: Publisher Site | Google Scholar
  53. Y.-C. Lee, C.-J. Cheng, M. A. Bilen et al., “BMP4 promotes prostate tumor growth in bone through osteogenesis,” Cancer Research, vol. 71, no. 15, pp. 5194–5203, 2011. View at: Publisher Site | Google Scholar
  54. K. Tanaka, T. Hirai, D. Kodama, H. Kondo, K. Hamamura, and A. Togari, “α1B -Adrenoceptor signalling regulates bone formation through the up-regulation of CCAAT/enhancer-binding protein delta expression in osteoblasts,” British Journal of Pharmacology, vol. 173, no. 6, pp. 1058–1069, 2016. View at: Publisher Site | Google Scholar
  55. A. Kalsbeek, I. F. Palm, S. E. La Fleur et al., “SCN outputs and the hypothalamic balance of life,” Journal of Biological Rhythms, vol. 21, no. 6, pp. 458–469, 2006. View at: Publisher Site | Google Scholar
  56. R. Dallmann, C. Touma, R. Palme, U. Albrecht, and S. Steinlechner, “Impaired daily glucocorticoid rhythm in Per1Brd mice,” Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, and Behavioral Physiology, vol. 192, no. 7, pp. 769–775, 2006. View at: Publisher Site | Google Scholar
  57. S. Yang, A. Liu, A. Weidenhammer et al., “The role of mPer2 clock gene in glucocorticoid and feeding rhythms,” Endocrinology, vol. 150, no. 5, pp. 2153–2160, 2009. View at: Publisher Site | Google Scholar
  58. X. Wu, G. Yu, H. Parks et al., “Circadian mechanisms in murine and human bone marrow mesenchymal stem cells following dexamethasone exposure,” Bone, vol. 42, no. 5, pp. 861–870, 2008. View at: Publisher Site | Google Scholar
  59. N. Nader, G. P. Chrousos, and T. Kino, “Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: potential physiological implications,” The FASEB Journal, vol. 23, no. 5, pp. 1572–1583, 2009. View at: Publisher Site | Google Scholar
  60. A. Rauch, S. Seitz, U. Baschant et al., “Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor,” Cell Metabolism, vol. 11, no. 6, pp. 517–531, 2010. View at: Publisher Site | Google Scholar
  61. Y. Fujihara, H. Kondo, T. Noguchi, and A. Togari, “Glucocorticoids mediate circadian timing in peripheral osteoclasts resulting in the circadian expression rhythm of osteoclast-related genes,” Bone, vol. 61, pp. 1–9, 2014. View at: Publisher Site | Google Scholar
  62. E. E. Benarroch, “Suprachiasmatic nucleus and melatonin: Reciprocal interactions and clinical correlations,” Neurology, vol. 71, no. 8, pp. 594–598, 2008. View at: Publisher Site | Google Scholar
  63. S. R. Pandi-Perumal, V. Srinivasan, G. J. M. Maestroni, D. P. Cardinali, B. Poeggeler, and R. Hardeland, “Melatonin: nature's most versatile biological signal?” FEBS Journal, vol. 273, no. 13, pp. 2813–2838, 2006. View at: Publisher Site | Google Scholar
  64. L. Zhang, P. Su, C. Xu et al., “Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression,” Journal of Pineal Research, vol. 49, no. 4, pp. 364–372, 2010. View at: Publisher Site | Google Scholar
  65. K.-H. Park, J. W. Kang, E.-M. Lee et al., “Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways,” Journal of Pineal Research, vol. 51, no. 2, pp. 187–194, 2011. View at: Publisher Site | Google Scholar
  66. H. Koyama, O. Nakade, Y. Takada, T. Kaku, and K.-H. W. Lau, “Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation,” Journal of Bone and Mineral Research, vol. 17, no. 7, pp. 1219–1229, 2002. View at: Publisher Site | Google Scholar
  67. P. A. Witt-Enderby, J. P. Slater, N. A. Johnson et al., “Effects on bone by the light/dark cycle and chronic treatment with melatonin and/or hormone replacement therapy in intact female mice,” Journal of Pineal Research, vol. 53, no. 4, pp. 374–384, 2012. View at: Publisher Site | Google Scholar
  68. M. P. Kotlarczyk, H. C. Lassila, C. K. O'Neil et al., “Melatonin osteoporosis prevention study (MOPS): A randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women,” Journal of Pineal Research, vol. 52, no. 4, pp. 414–426, 2012. View at: Publisher Site | Google Scholar
  69. P. C. Yannielli, P. C. Molyneux, M. E. Harrington, and D. A. Golombek, “Ghrelin effects on the circadian system of mice,” The Journal of Neuroscience, vol. 27, no. 11, pp. 2890–2895, 2007. View at: Publisher Site | Google Scholar
  70. E. W. Lamont, J. Bruton, I. D. Blum, and A. Abizaid, “Ghrelin receptor-knockout mice display alterations in circadian rhythms of activity and feeding under constant lighting conditions,” European Journal of Neuroscience, vol. 39, no. 2, pp. 207–217, 2014. View at: Publisher Site | Google Scholar
  71. K. W. Oh, W. Y. Lee, E. J. Rhee et al., “The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men,” Clinical Endocrinology, vol. 63, no. 2, pp. 131–138, 2005. View at: Publisher Site | Google Scholar
  72. L. A. Weiss, E. Barrett-Connor, D. Von Mühlen, and P. Clark, “Leptin predicts BMD and bone resorption in older women but not older men: The Rancho Bernardo Study,” Journal of Bone and Mineral Research, vol. 21, no. 5, pp. 758–764, 2006. View at: Publisher Site | Google Scholar
  73. W. D. Fraser, A. M. Ahmad, and J. P. Vora, “The physiology of the circadian rhythm of parathyroid hormone and its potential as a treatment for osteoporosis,” Current Opinion in Nephrology and Hypertension, vol. 13, no. 4, pp. 437–444, 2004. View at: Publisher Site | Google Scholar
  74. R. Hanyu, T. Hayata, M. Nagao et al., “Per-1 is a specific clock gene regulated by parathyroid hormone (PTH) signaling in osteoblasts and is functional for the transcriptional events induced by PTH,” Journal of Cellular Biochemistry, vol. 112, no. 2, pp. 433–438, 2011. View at: Publisher Site | Google Scholar
  75. N. Okubo, H. Fujiwara, Y. Minami et al., “Parathyroid hormone resets the cartilage circadian clock of the organ-cultured murine femur,” Acta Orthopaedica, vol. 86, no. 5, pp. 627–631, 2015. View at: Publisher Site | Google Scholar
  76. T. Kunimoto, N. Okubo, Y. Minami et al., “A PTH-responsive circadian clock operates in ex vivo mouse femur fracture healing site,” Scientific Reports, vol. 6, 2016. View at: Google Scholar
  77. R. Zhang, N. F. Lahens, H. I. Ballance, M. E. Hughes, and J. B. Hogenesch, “A circadian gene expression atlas in mammals: implications for biology and medicine,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 111, no. 45, pp. 16219–16224, 2014. View at: Publisher Site | Google Scholar
  78. L. Yan, “Expression of clock genes in the suprachiasmatic nucleus: Effect of environmental lighting conditions,” Reviews in Endocrine and Metabolic Disorders, vol. 10, no. 4, pp. 301–310, 2009. View at: Publisher Site | Google Scholar
  79. H. Boucher, V. Vanneaux, T. Domet, A. Parouchev, and J. Larghero, “Circadian clock genes modulate human bone marrow mesenchymal stem cell differentiation, migration and cell cycle,” PLoS ONE, vol. 11, no. 1, 2016. View at: Google Scholar
  80. M. H. Vitaterna, D. P. King, A.-M. Chang et al., “Mutagenesis and mapping of a mouse gene, clock, essential for circadian behavior,” Science, vol. 264, no. 5159, pp. 719–725, 1994. View at: Publisher Site | Google Scholar
  81. J. P. DeBruyne, E. Noton, C. M. Lambert, E. S. Maywood, D. R. Weaver, and S. M. Reppert, “A clock shock: mouse CLOCK is not required for circadian oscillator function,” Neuron, vol. 50, no. 3, pp. 465–477, 2006. View at: Publisher Site | Google Scholar
  82. J. P. DeBruyne, D. R. Weaver, and S. M. Reppert, “CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock,” Nature Neuroscience, vol. 10, no. 5, pp. 543–545, 2007. View at: Publisher Site | Google Scholar
  83. G. Yuan, B. Hua, Y. Yang et al., “The Circadian Gene Clock Regulates Bone Formation Via PDIA3,” Journal of Bone and Mineral Research, vol. 32, no. 4, pp. 861–871, 2017. View at: Publisher Site | Google Scholar
  84. Y. Wang, A. Nizkorodov, K. Riemenschneider et al., “Impaired bone formation in pdia3 deficient mice,” PLoS ONE, vol. 9, no. 11, 2014. View at: Google Scholar
  85. M. K. Bunger, L. D. Wilsbacher, S. M. Moran et al., “Mop3 is an essential component of the master circadian pacemaker in mammals,” Cell, vol. 103, no. 7, pp. 1009–1017, 2000. View at: Publisher Site | Google Scholar
  86. R. V. Kondratov, A. A. Kondratova, V. Y. Gorbacheva, O. V. Vykhovanets, and M. P. Antoch, “Early aging and age-related pathologies in mice deficient in BMAL1, the core component of the circadian clock,” Genes & Development, vol. 20, no. 14, pp. 1868–1873, 2006. View at: Publisher Site | Google Scholar
  87. W. E. Samsa, A. Vasanji, R. J. Midura, and R. V. Kondratov, “Deficiency of circadian clock protein BMAL1 in mice results in a low bone mass phenotype,” Bone, vol. 84, pp. 194–203, 2016. View at: Publisher Site | Google Scholar
  88. T. Takarada, C. Xu, H. Ochi et al., “Bone Resorption Is Regulated by Circadian Clock in Osteoblasts,” Journal of Bone and Mineral Research, vol. 32, no. 4, pp. 872–881, 2017. View at: Publisher Site | Google Scholar
  89. K. Bae, X. Jin, E. S. Maywood, M. H. Hastings, S. M. Reppert, and D. R. Weaver, “Differential functions of mPer1, mPer2, and mPer3 in the SCN circadian clock,” Neuron, vol. 30, no. 2, pp. 525–536, 2001. View at: Publisher Site | Google Scholar
  90. L. P. Shearman, M. J. Zylka, D. R. Weaver, L. F. Kolakowski Jr., and S. M. Reppert, “Two period homologs: Circadian expression and photic regulation in the suprachiasmatic nuclei,” Neuron, vol. 19, no. 6, pp. 1261–1269, 1997. View at: Publisher Site | Google Scholar
  91. L. Fu, M. S. Patel, A. Bradley, E. F. Wagner, and G. Karsenty, “The molecular clock mediates leptin-regulated bone formation,” Cell, vol. 122, no. 5, pp. 803–815, 2005. View at: Publisher Site | Google Scholar
  92. E. Maronde, A. F. Schilling, S. Seitz et al., “The clock genes Period 2 and Cryptochrome 2 differentially balance bone formation,” PLoS ONE, vol. 5, no. 7, 2010. View at: Google Scholar
  93. M. H. Vitaterna, C. P. Selby, T. Todo et al., “Differential regulation of mammalian period genes and circadian rhythmicity by cryptochromes 1 and 2,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 96, no. 21, pp. 12114–12119, 1999. View at: Publisher Site | Google Scholar
  94. B. Zheng, U. Albrecht, K. Kaasik et al., “Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock,” Cell, vol. 105, no. 5, pp. 683–694, 2001. View at: Publisher Site | Google Scholar
  95. R. J. Thresher, M. H. Vitaterna, Y. Miyamoto et al., “Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses,” Science, vol. 282, no. 5393, pp. 1490–1494, 1998. View at: Publisher Site | Google Scholar
  96. Y. Li, J. Zhou, Y. Wu et al., “Association of osteoporosis with genetic variants of circadian genes in Chinese geriatrics,” Osteoporosis International, vol. 27, no. 4, pp. 1485–1492, 2016. View at: Publisher Site | Google Scholar
  97. A. Bugge, D. Feng, L. J. Everett et al., “Rev-erbα and Rev-erbβ coordinately protect the circadian clock and normal metabolic function,” Genes & Development, vol. 26, no. 7, pp. 657–667, 2012. View at: Publisher Site | Google Scholar
  98. E. Woldt, Y. Sebti, L. A. Solt et al., “Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy,” Nature Medicine, vol. 19, no. 8, pp. 1039–1046, 2013. View at: Publisher Site | Google Scholar
  99. J. M. Yu, X. Wu, J. M. Gimble, X. Guan, M. A. Freitas, and B. A. Bunnell, “Age-related changes in mesenchymal stem cells derived from rhesus macaque bone marrow,” Aging Cell, vol. 10, no. 1, pp. 66–79, 2011. View at: Publisher Site | Google Scholar
  100. Y. He, F. Lin, Y. Chen, Z. Tan, D. Bai, and Q. Zhao, “Overexpression of the circadian clock gene rev-erbα affects murine bone mesenchymal stem cell proliferation and osteogenesis,” Stem Cells and Development, vol. 24, no. 10, pp. 1194–1204, 2015. View at: Publisher Site | Google Scholar
  101. A. Medvedev, Z.-H. Yan, T. Hirose, V. Giguère, and A. M. Jetten, “Cloning of a cDNA encoding the murine orphan receptor RZR/RORγ and characterization of its response element,” Gene, vol. 181, no. 1-2, pp. 199–206, 1996. View at: Publisher Site | Google Scholar
  102. M. Akashi and T. Takumi, “The orphan nuclear receptor RORα regulates circadian transcription of the mammalian core-clock Bmal1,” Nature Structural & Molecular Biology, vol. 12, no. 5, pp. 441–448, 2005. View at: Publisher Site | Google Scholar
  103. M. I. Masana, I. C. Sumaya, M. Becker-Andre, and M. L. Dubocovich, “Behavioral characterization and modulation of circadian rhythms by light and melatonin in C3H/HeN mice homozygous for the RORβ knockout,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 292, no. 6, pp. R2357–R2367, 2007. View at: Publisher Site | Google Scholar
  104. T. Meyer, M. Kneissel, J. Mariani, and B. Fournier, “In vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolism,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 97, no. 16, pp. 9197–9202, 2000. View at: Publisher Site | Google Scholar
  105. J. A. R. Gordon, C. E. Tye, A. V. Sampaio, T. M. Underhill, G. K. Hunter, and H. A. Goldberg, “Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro,” Bone, vol. 41, no. 3, pp. 462–473, 2007. View at: Publisher Site | Google Scholar
  106. M. M. Roforth, S. Khosla, and D. G. Monroe, “Identification of Rorβ targets in cultured osteoblasts and in human bone,” Biochemical and Biophysical Research Communications, vol. 440, no. 4, pp. 768–773, 2013. View at: Publisher Site | Google Scholar
  107. M. M. Roforth, G. Liu, S. Khosla, and D. G. Monroe, “Examination of nuclear receptor expression in osteoblasts reveals rorβ as an important regulator of osteogenesis,” Journal of Bone and Mineral Research, vol. 27, no. 4, pp. 891–901, 2012. View at: Publisher Site | Google Scholar
  108. J. N. Farr, M. M. Weivoda, K. M. Nicks et al., “Osteoprotection Through the Deletion of the Transcription Factor Rorβ in Mice,” Journal of Bone and Mineral Research, vol. 33, no. 4, pp. 720–731, 2018. View at: Publisher Site | Google Scholar
  109. A. Nakashima, T. Kawamoto, K. K. Honda et al., “DEC1 modulates the circadian phase of clock gene expression,” Molecular and Cellular Biology, vol. 28, no. 12, pp. 4080–4092, 2008. View at: Publisher Site | Google Scholar
  110. Y. He, C. R. Jones, N. Fujiki et al., “The transcriptional repressor DEC2 regulates sleep length in mammals,” Science, vol. 325, no. 5942, pp. 866–870, 2009. View at: Publisher Site | Google Scholar
  111. T. Iwata, T. Kawamoto, E. Sasabe et al., “Effects of overexpression of basic helix-loop-helix transcription factor Dec1 on osteogenic and adipogenic differentiation of mesenchymal stem cells,” European Journal of Cell Biology, vol. 85, no. 5, pp. 423–431, 2006. View at: Publisher Site | Google Scholar
  112. M. Shen, E. Yoshida, W. Yan et al., “Basic helix-loop-helix protein DEC1 promotes chondrocyte differentiation at the early and terminal stages,” The Journal of Biological Chemistry, vol. 277, no. 51, pp. 50112–50120, 2002. View at: Publisher Site | Google Scholar
  113. D. D. Bikle, E. Gee, B. Halloran, M. A. Kowalski, E. Ryzen, and J. G. Haddad, “Assessment of the free fraction of 25-hydroxyvitamin d in serum and its regulation by albumin and the vitamin d-binding protein,” The Journal of Clinical Endocrinology & Metabolism, vol. 63, no. 4, pp. 954–959, 1986. View at: Publisher Site | Google Scholar
  114. G. B. Schneider, K. A. Benis, N. W. Flay, R. A. Ireland, and S. N. Popoff, “Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations,” Bone, vol. 16, no. 6, pp. 657–662, 1995. View at: Publisher Site | Google Scholar
  115. P. Fonjallaz, V. Ossipow, G. Wanner, and U. Schibler, “The two PAR leucine zipper proteins, TEF and DBP, display similar circadian and tissue-specific expression, but have different target promoter preferences,” EMBO Journal, vol. 15, no. 2, pp. 351–362, 1996. View at: Publisher Site | Google Scholar
  116. M. Pekkinen, E. Saarnio, H. T. Viljakainen et al., “Vitamin D binding protein genotype is associated with serum 25-hydroxyvitamin D and PTH concentrations, as well as bone health in children and adolescents in Finland,” PLoS ONE, vol. 9, no. 1, 2014. View at: Google Scholar
  117. R. I. Khusainova, L. I. Seleznyova, A. V. Mal'Tsev et al., “Associations between vitamin D-binding protein (DBP) gene polymorphism (TAAA)nand development of osteoporosis in the Volga-Ural Region of Russia,” Bulletin of Experimental Biology and Medicine, vol. 157, no. 2, pp. 253–257, 2014. View at: Publisher Site | Google Scholar
  118. Z. H. Al-Oanzi, S. P. Tuck, S. S. Mastana et al., “Vitamin D-binding protein gene microsatellite polymorphism influences BMD and risk of fractures in men,” Osteoporosis International, vol. 19, no. 7, pp. 951–960, 2008. View at: Publisher Site | Google Scholar
  119. D.-H. Xiong, H. Shen, L.-J. Zhao et al., “Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction,” Journal of Bone and Mineral Research, vol. 21, no. 11, pp. 1678–1695, 2006. View at: Publisher Site | Google Scholar
  120. F. F. Safadi, P. Thornton, H. Magiera et al., “Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein,” The Journal of Clinical Investigation, vol. 103, no. 2, pp. 239–251, 1999. View at: Publisher Site | Google Scholar
  121. Y. Yamanaka, Y. Suzuki, T. Todo, K.-I. Honma, and S. Honma, “Loss of circadian rhythm and light-induced suppression of pineal melatonin levels in Cry1 and Cry2 double-deficient mice,” Genes to Cells, vol. 15, no. 10, pp. 1063–1071, 2010. View at: Publisher Site | Google Scholar
  122. N. Preitner, F. Damiola, L. Lopez-Molina et al., “The orphan nuclear receptor REV-ERBα controls circadian transcription within the positive limb of the mammalian circadian oscillator,” Cell, vol. 110, no. 2, pp. 251–260, 2002. View at: Publisher Site | Google Scholar
  123. H. Cho, X. Zhao, M. Hatori et al., “Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β,” Nature, vol. 485, no. 7396, pp. 123–127, 2012. View at: Publisher Site | Google Scholar
  124. L. Lopez-Molina, F. Conquet, M. Dubois-Dauphin, and U. Schibler, “The DBP gene is expressed according to a circadian rhythm in the suprachiasmatic nucleus and influences circadian behavior,” EMBO Journal, vol. 16, no. 22, pp. 6762–6771, 1997. View at: Publisher Site | Google Scholar
  125. M. A. Karsdal, I. Byrjalsen, B. J. Riis, and C. Christiansen, “Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin,” BMC Clinical Pharmacology, vol. 8, 2008. View at: Google Scholar
  126. D. Michalska, M. Luchavova, V. Zikan, I. Raska Jr., A. A. Kubena, and J. J. Stepan, “Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis,” Osteoporosis International, vol. 23, no. 12, pp. 2885–2891, 2012. View at: Publisher Site | Google Scholar
  127. D. Jing, G. Shen, J. Huang et al., “Circadian rhythm affects the preventive role of pulsed electromagnetic fields on ovariectomy-induced osteoporosis in rats,” Bone, vol. 46, no. 2, pp. 487–495, 2010. View at: Publisher Site | Google Scholar
  128. N. C. Wright, A. C. Looker, K. G. Saag et al., “The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar,” Journal of Bone and Mineral Research, 2014. View at: Publisher Site | Google Scholar
  129. S. W. Blume and J. R. Curtis, “Medical costs of osteoporosis in the elderly Medicare population,” Osteoporosis International, vol. 22, no. 6, pp. 1835–1844, 2011. View at: Publisher Site | Google Scholar
  130. E. S. Musiek, “Circadian clock disruption in neurodegenerative diseases: cause and effect?” Frontiers in Pharmacology, vol. 6, 2015. View at: Publisher Site | Google Scholar
  131. N. N. Guerrero-Vargas, R. Navarro-Espíndola, M. A. Guzmán-Ruíz et al., “Circadian disruption promotes tumor growth by anabolic host metabolism; experimental evidence in a rat model,” BMC Cancer, vol. 17, no. 1, 2017. View at: Google Scholar
  132. L. Chen and G. Yang, “Recent advances in circadian rhythms in cardiovascular system,” Frontiers in Pharmacology, vol. 6, article 71, 2015. View at: Publisher Site | Google Scholar
  133. Y. Wang, N. Kumar, L. A. Solt et al., “Modulation of retinoic acid receptor-related orphan receptor α and γ activity by 7-oxygenated sterol ligands,” The Journal of Biological Chemistry, vol. 285, no. 7, pp. 5013–5025, 2010. View at: Publisher Site | Google Scholar
  134. G. Sulli, A. Rommel, X. Wang et al., “Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence,” Nature, vol. 553, no. 7688, pp. 351–355, 2018. View at: Publisher Site | Google Scholar
  135. L. A. Solt, S. Banerjee, S. Campbell, T. M. Kamenecka, and T. P. Burris, “ROR inverse agonist suppresses insulitis and prevents hyperglycemia in a mouse model of type 1 diabetes,” Endocrinology, vol. 156, no. 3, pp. 869–881, 2015. View at: Publisher Site | Google Scholar
  136. S. Sitaula, C. Billon, T. M. Kamenecka, L. A. Solt, and T. P. Burris, “Suppression of atherosclerosis by synthetic REV-ERB agonist,” Biochemical and Biophysical Research Communications, vol. 460, no. 3, pp. 566–571, 2015. View at: Publisher Site | Google Scholar
  137. Y. Wang, C. Billon, J. K. Walker, and T. P. Burris, “Therapeutic effect of a synthetic RORalpha/gamma agonist in an animal model of autism,” ACS Chemical Neuroscience, vol. 7, no. 2, pp. 143–148, 2016. View at: Google Scholar
  138. D. J. Kojetin and T. P. Burris, “REV-ERB and ROR nuclear receptors as drug targets,” Nature Reviews Drug Discovery, vol. 13, no. 3, pp. 197–216, 2014. View at: Publisher Site | Google Scholar

Copyright © 2018 Chao Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1983 Views | 553 Downloads | 4 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.